Parkinson disease

This phase 3 trial tests whether adding vibostolimab to pembrolizumab (Keytruda) helps people with PD-L1 positive metastatic non-small cell lung cancer live longer than pembrolizumab alone. Over 1,200 participants received either the combination or pembrolizumab every three weeks…

This study tested whether a combination of olaparib (a targeted therapy) and pembrolizumab (an immunotherapy) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that initially responded to chemo-immunotherapy. The tri…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…

This study tests whether adding lenvatinib to pembrolizumab and chemotherapy helps people with metastatic esophageal cancer live longer. About 864 participants receive either the new three-drug combo or standard care. The goal is to improve overall survival, but this is not a cur…

This trial tests whether adding augmented reality (AR) to treadmill training can help people with Parkinson's disease who have trouble walking and are at risk of falling. Participants will be randomly assigned to one of three groups: treadmill training with AR, treadmill training…

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This early-stage trial tested the safety of an intravenous drug called talineuren (liposomal GM1) in 22 people with Parkinson's disease. The study was open-label and designed to find a safe dose, but it was terminated before completion. No conclusions about effectiveness can be d…

This study looked at whether taking UCB0599 early or later could slow brain changes in people with Parkinson's disease. It involved 428 adults who had already completed an earlier study. The trial was stopped early, but researchers measured brain scans and medication use over 18 …

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…

This study tested an experimental drug called VENT-02 in 29 people with mild to moderate Parkinson's disease. The drug aims to reduce brain inflammation by blocking a protein called NLRP3. The trial was terminated early, so we don't have clear results on whether it helps symptoms…

This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…

This early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with P…

This study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…

This study tested whether N-acetylcysteine (NAC), an antioxidant, could help reduce impulse control disorders caused by Parkinson's medications. Only 14 people with mild-to-moderate symptoms were enrolled before the trial was stopped early. The goal was to see if 10 weeks of NAC …

This study tested a robotic device called the G-EO Gait Trainer to help people with Parkinson's disease improve their walking. The device supports the body and guides leg movements to make walking practice safer and more effective. The trial was terminated early, so only limited …

This study looked at whether using walking poles during an 8-week independent walking program could improve walking and activity levels in people with Parkinson's disease. Eleven participants were assigned to walk with or without poles at least three times a week. The trial was t…

This study looked at whether the drug safinamide (Xadago) could improve sleep quality in people with Parkinson's disease. Eleven participants took safinamide for 12 weeks while their sleep was measured. The trial was terminated early, so the results are not conclusive.

This study tested whether istradefylline, a drug already approved for motor symptoms in Parkinson's, could also improve apathy and motivation. Only 8 people enrolled before the trial was terminated early. The results are too limited to draw any conclusions.

This study tested whether a high-dose magnetic stimulation (TMS) targeting both motor and cognitive brain areas could better reduce freezing of gait in people with Parkinson's disease compared to standard low-dose stimulation of just the motor area. The trial planned to enroll 64…

This study tested an inhaled form of apomorphine (AZ-009) to quickly treat 'OFF' episodes in people with Parkinson's disease—times when symptoms like stiffness or trouble moving return between regular medication doses. The trial was planned for more participants but was terminate…

This study looked at how anesthesia changes brain activity in people with Parkinson's disease or essential tremor who were already scheduled for deep brain stimulation (DBS) surgery. Researchers recorded brain signals during a short period of anesthesia to understand which circui…

This study aimed to find brain and movement markers in people with a type of depression that doesn't respond to standard antidepressants, called anhedonic depression. Researchers measured brain waves (P300), walking speed, and hand movements in 36 participants. The goal was to id…

This study looked at whether intensive treadmill exercise can improve motor symptoms and reduce inflammation in people with early-stage Parkinson's disease. Researchers measured changes in movement scores and blood markers of nerve damage and inflammation in 30 patients who eithe…